842 related articles for article (PubMed ID: 18691996)
21. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
23. [Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Ruiz García A; Gordillo López FJ; Arranz Martínez E; Hermosa Hernán JC
Med Clin (Barc); 2011 Jun; 137(3):119-25. PubMed ID: 21074814
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
25. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Edwards JE; Moore RA
BMC Fam Pract; 2003 Dec; 4():18. PubMed ID: 14969594
[TBL] [Abstract][Full Text] [Related]
26. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Juszczyk MA; Seip RL; Thompson PD
Prev Cardiol; 2005; 8(4):197-9. PubMed ID: 16230873
[TBL] [Abstract][Full Text] [Related]
27. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
[TBL] [Abstract][Full Text] [Related]
28. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Lachaine J; Merikle E; Tarride JE; Montpetit M; Rinfret S
Clin Ther; 2007 Mar; 29(3):519-28. PubMed ID: 17577472
[TBL] [Abstract][Full Text] [Related]
29. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
30. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
[TBL] [Abstract][Full Text] [Related]
31. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
[TBL] [Abstract][Full Text] [Related]
32. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
33. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
[TBL] [Abstract][Full Text] [Related]
34. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
35. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
Palmer SJ; Brady AJ; Ratcliffe AE
Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
38. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
